Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ BLPH opened at $0.06 on Tuesday. The stock has a 50-day moving average of $0.06 and a 200 day moving average of $0.05. The company has a market capitalization of $684,880.00, a price-to-earnings ratio of -0.07 and a beta of 0.71. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.76.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.